Sylvirene Numbing

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the temporary relief of pain and itching associated with minor burns, sunburn, insect bites, scrapes, and minor skin irritations.

Limitations of Use: This product is intended for external use only and should not be applied to large areas of the body or on deep puncture wounds, animal bites, or serious burns.

Dosage and Administration

Healthcare professionals are advised to cleanse the targeted skin area thoroughly and pat it dry before application. A thin layer of the medication should be applied to the affected area. This application may be performed up to 3 to 4 times daily, ensuring that the total daily applications do not exceed this frequency.

Contraindications

Use is contraindicated in the following situations:

Application on large areas of the body is not recommended due to the potential for systemic absorption and associated adverse effects. The product should not be applied to broken, blistered, or abraded skin, as this may increase the risk of irritation or systemic toxicity. Additionally, use is contraindicated in individuals with a known allergy to local anesthetics, including lidocaine, benzocaine, or other "caine" derivatives, due to the risk of severe allergic reactions.

Warnings and Precautions

For external use only. This product is not intended for internal use, and ingestion may lead to serious health consequences. In the event of accidental ingestion, it is imperative to seek emergency medical assistance or contact a Poison Control Center immediately.

Healthcare professionals should advise patients to discontinue use and consult a physician if any of the following occur: the condition being treated worsens or fails to improve within 7 days; an allergic reaction to any of the product's ingredients is suspected; or if symptoms persist without relief, accompanied by redness or irritation at the application site. Monitoring for these adverse reactions is essential to ensure patient safety and effective treatment outcomes.

Side Effects

Patients using this product should be aware that it is intended for external use only. In clinical practice, it is important to monitor for any adverse reactions that may arise during treatment.

Serious adverse reactions may include allergic reactions to the ingredients in the product. Patients experiencing such reactions should discontinue use immediately and seek medical attention.

Common adverse reactions may involve worsening of the condition being treated or failure to improve within 7 days of use. If patients notice that their symptoms do not subside, or if they experience redness or irritation, they are advised to stop using the product and consult a healthcare professional.

It is crucial for patients to be vigilant about their response to the treatment and to communicate any concerns regarding adverse reactions to their healthcare provider.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Sylvirene Numbing (menthol 5% numbing). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

There is no information regarding the use of Sylvirene Numbing (menthol 5% numbing cream) in pregnant patients, including safety concerns, dosage modifications, or special precautions during pregnancy. Healthcare professionals should consider the lack of data when prescribing this medication to women of childbearing potential and weigh the potential risks versus benefits. Given the absence of specific information, caution is advised in the use of this product during pregnancy.

Lactation

There is no specific information regarding the use of Sylvirene Numbing (menthol 5% numbing cream) in lactating mothers or its effects on breastfed infants. Healthcare professionals should consider the lack of data when advising lactating mothers on the use of this product.

Renal Impairment

Patients with renal impairment may require dosage adjustments due to reduced renal function. It is essential to monitor renal function tests regularly in individuals with known kidney problems. For patients with a creatinine clearance of less than 30 mL/min, a reduced dose should be considered to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

There is currently no specific information available regarding overdosage for this medication. Healthcare professionals are advised to monitor patients closely for any signs of adverse effects or symptoms that may arise from excessive dosing.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Patients should be evaluated for potential complications, and appropriate interventions should be implemented based on clinical judgment.

For further guidance, healthcare professionals may refer to established protocols for managing drug overdosage or consult a poison control center.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Patients should be advised to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. Healthcare providers should emphasize the importance of avoiding application on large areas of the body, as well as on broken, blistered, or abraded skin.

It is crucial to inform patients to disclose any known allergies to local anesthetics, including lidocaine, benzocaine, or other "caine" derivatives, prior to using the product. Patients should be instructed to monitor their condition closely; if symptoms do not improve or worsen within 7 days, they should contact their healthcare provider.

Patients must be made aware of the potential for allergic reactions to the ingredients in the product. They should be advised to discontinue use and seek medical attention if they experience any signs of an allergic reaction or if symptoms being treated do not subside, or if redness or irritation occurs.

Healthcare providers should instruct patients to avoid contact with the eyes and to refrain from tightly bandaging the area or using a heating pad in conjunction with the product. Finally, it is essential to remind patients to use the product only as directed to ensure safety and efficacy.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It should be stored at a temperature range of 15-30°C (59-86°F) to maintain its efficacy. Care must be taken to protect the product from excessive heat and direct sunlight to ensure optimal storage conditions. It is essential to use the product only as directed to ensure safety and effectiveness.

Additional Clinical Information

The medication is administered topically, with a recommended application of a thin layer to the affected area, not exceeding 3-4 times daily. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Sylvirene Numbing, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)